Acutaas Chemicals Ltd vs Sakar Healthcare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Acutaas Chemicals Ltd is ₹ 2797 as of 18 May 15:30 . The P/E Ratio of Acutaas Chemicals Ltd changed from 50.6 on March 2022 to 125.9 on March 2025 . This represents a CAGR of 25.59% over 4 yearsThe P/E Ratio of Sakar Healthcare Ltd changed from 16.5 on March 2021 to 26.6 on March 2025 . This represents a CAGR of 10.02% over 5 years The Market Cap of Acutaas Chemicals Ltd changed from ₹ 3642 crore on March 2022 to ₹ 9994 crore on March 2025 . This represents a CAGR of 28.70% over 4 yearsThe Market Cap of Sakar Healthcare Ltd changed from ₹ 176.64 crore on March 2021 to ₹ 464.72 crore on March 2025 . This represents a CAGR of 21.34% over 5 years The revenue of Acutaas Chemicals Ltd for the Mar '26 is ₹ 443.86 crore as compare to the Dec '25 revenue of ₹ 397.88 crore. This represent the growth of 11.56% The revenue of Sakar Healthcare Ltd for the Mar '26 is ₹ 71.27 crore as compare to the Dec '25 revenue of ₹ 70.85 crore. This represent the growth of 0.59% The ebitda of Acutaas Chemicals Ltd for the Mar '26 is ₹ 194.62 crore as compare to the Dec '25 ebitda of ₹ 155.35 crore. This represent the growth of 25.28% The ebitda of Sakar Healthcare Ltd for the Mar '26 is ₹ 26.41 crore as compare to the Dec '25 ebitda of ₹ 19.1 crore. This represent the growth of 38.27% The net profit of Acutaas Chemicals Ltd changed from ₹ 14.69 crore to ₹ 134.28 crore over 8 quarters. This represents a CAGR of 202.34% The net profit of Sakar Healthcare Ltd changed from ₹ 2.41 crore to ₹ 11.02 crore over 8 quarters. This represents a CAGR of 113.84% The Dividend Payout of Acutaas Chemicals Ltd changed from 15.19 % on March 2022 to 7.7 % on March 2025 . This represents a CAGR of -15.62% over 4 yearsThe Dividend Payout of Sakar Healthcare Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Acutaas Chemicals Ltd

Acutaas Chemicals Limited was initially formed as partnership firm in the name of 'Ami Organics' on 3 January, 2004 at Surat, India.
The Firm converted into a Private Limited Company under the name of 'Ami Organics Private Limited' with a Certificate of Incorporation dated 12 June, 2007.
Subsequently, the Company was converted into a Public Limited Company, reflecting the change in name of the Company to 'Ami Organics Limited' on April 18, 2018.
The name of the Company has now changed to Acutaas Chemicals Limited with effect from May 15, 2025, pursuant to the receipt of Fresh Certificate of Incorporation from the Registrar of Companies. The Company is engaged in business of drugs intermediate chemicals and related activities.
The Company is one of the major manufacturers of Pharma Intermediates for certain key APIs, including Dolutegravir, Trazodone, Entacapone, Nintedanib and Rivaroxaban.

About Sakar Healthcare Ltd

Sakar Healthcare Limited was incorporated as a Private Limited Company under the name 'Sakar Healthcare Private Limited on 26th March 2004.
Subsequently, the Company was converted into Public Limited Company on March 27, 2015 and the name of the Company was changed to 'Sakar Healthcare Limited.
The Company is promoted by Sanjay Shah, Rita Shah and Aarsh Shah. The Company is engaged in manufacturing of Pharmaceutical products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials & Lyophilized Injections and Oral Solid Dossages.
It manufactures and markets pharmaceutical formulations relating to analgesics, anti coagulants, anti malarial, anti spasmodic, antianemics, antibiotics, anti-emetics, anti-histamines, bronchodilators, corticosteroids, cough and cold preparations, multivitamins, etc.

FAQs for the comparison of Acutaas Chemicals Ltd and Sakar Healthcare Ltd

Which company has a larger market capitalization, Acutaas Chemicals Ltd or Sakar Healthcare Ltd?

Market cap of Acutaas Chemicals Ltd is 22,902 Cr while Market cap of Sakar Healthcare Ltd is 1,735 Cr

What are the key factors driving the stock performance of Acutaas Chemicals Ltd and Sakar Healthcare Ltd?

The stock performance of Acutaas Chemicals Ltd and Sakar Healthcare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Acutaas Chemicals Ltd and Sakar Healthcare Ltd?

As of May 18, 2026, the Acutaas Chemicals Ltd stock price is INR ₹2797.35. On the other hand, Sakar Healthcare Ltd stock price is INR ₹779.95.

How do dividend payouts of Acutaas Chemicals Ltd and Sakar Healthcare Ltd compare?

To compare the dividend payouts of Acutaas Chemicals Ltd and Sakar Healthcare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.